A lesser known valuation approach for biopharmaceutical products offers project managers and out-licensing biotech companies an edge in budget and license negotiations.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Fernández, P. Valuing real options: frequently made errors. Journal of Financial Transformations, 13, 77–81 (2005).
Dimasi, J.A. Risks in new drug development: approval success rates for investigational drugs. Clin. Pharmacol. Ther. 69, 297–307 (2001).
Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711–715 (2004).
Tufts Center for the Study of Drug Development. Outlook 2005. Tufts Outlook Report. (Tufts Center, Medford, MA, USA, 2005).
Grabowski, H.G. & Vernon, J. The distribution of sales revenues from pharmaceutical innovation. Pharmacoeconomics 18 Suppl 1, 21–32 (2000).
Author information
Authors and Affiliations
Supplementary information
Related links
Related links
Related links in Nature Research
Rights and permissions
About this article
Cite this article
Villiger, R., Bogdan, B. Getting real about valuations in biotech. Nat Biotechnol 23, 423–428 (2005). https://doi.org/10.1038/nbt0405-423
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0405-423
This article is cited by
-
Pharmaceutical patent evaluation and licensing using a stochastic model and Monte Carlo simulations
Nature Biotechnology (2011)
-
A very firm handshake: biotech's growing negotiating power
Nature Biotechnology (2005)
